Aggregometry Response to Half-dose Prasugrel in Flow-diverting Stent Implantation

Basit Öğe Kaydı
dc.contributor.authorOran, Ismail
dc.contributor.authorCinar, Celal
dc.contributor.authorGok, Mustafa
dc.contributor.authorDuzgun, Fatih
dc.date.accessioned2020-12-01T11:58:21Z
dc.date.available2020-12-01T11:58:21Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose the aim of this study was to determine whether half-dose loading (30/mg) of prasugrel is sufficient to achieve adequate platelet inhibition, and whether such a loading dose of prasugrel together with aspirin followed by a 10/mg/day prasugrel maintenance, could serve as a first-line antiplatelet strategy for patients undergoing flow-diverting stent (FDS) implantation. Methods Data from a group of consecutive patients treated for intracranial aneurysm with FDS were retrospectively collected. Platelet P2Y12 receptor responsiveness was assessed by a rapid platelet function test just prior to the procedure. All ischemic and hemorrhagic complications as well as morbidity and mortality rates were documented. Results A total of 138 patients with 153 aneurysms (32 were symptomatic and 121 were incidental) underwent FDS treatment in a total of 147 loading sessions. Adequate platelet inhibition was obtained in 136/138 (98.5%) patients and 145/147 (98.6%) loading sessions. Overall, there was one case of (hemorrhagic) mortality (0.7%), one of (ischemic) morbidity (0.7%), one of symptomatic (hemorrhagic) clinical complications without permanent deficits (0.7%), and six transient ischemic attacks (4.1%). the 6-month control angiography, available for all patients, revealed a 95.4% aneurysm occlusion rate. Conclusion Half-dose (30/mg) prasugrel loading results in effective platelet P2Y12 receptor inhibition in more than 98% of patients. Dual antiaggregant loading with half dose prasugrel followed by prasugrel maintenance as a first-line therapy appears to be feasible in patients treated with FDS implantation for intracranial aneurysm.en_US
dc.identifier.doi10.1007/s00062-019-00804-1en_US
dc.identifier.endpage469en_US
dc.identifier.issn1869-1439
dc.identifier.issn1869-1447
dc.identifier.issue3en_US
dc.identifier.pmid31165176en_US
dc.identifier.startpage463en_US
dc.identifier.urihttps://doi.org/10.1007/s00062-019-00804-1
dc.identifier.urihttps://hdl.handle.net/11454/61997
dc.identifier.volume30en_US
dc.identifier.wosWOS:000566420700006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofClinical Neuroradiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAneurysmen_US
dc.subjectAntiplatelet agentsen_US
dc.subjectFlow diversionen_US
dc.subjectPlatelet function testen_US
dc.subjectLoading doseen_US
dc.titleAggregometry Response to Half-dose Prasugrel in Flow-diverting Stent Implantationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu